EULAR Recommendations for Physical Activity in Arthritis
EULAR has published a 2025 update for physical activity recommendations for patients with osteoarthritis (OA) and rheumatoid arthritis (RA).
Read Article
Knee pain: JAMA review
- 5% PCP visits knee pain
- Knee OA ~654 million worldwide
- Patellofemoral pain: <40 yrs & physically active; pain on squat
- Meniscal tears in 12% adults (McMurray 61% sensitive; 84% specific; Joint line tender 83% sensitive; 83% specific) https://t.co/M7om9DN7Zu
Dr. John Cush @RheumNow( View Tweet )
Prospective study of 305 Consecutive newly diagnosed axSpA pts (55% male; Dx delay 6 yrs; 75% B27+). 56% w/ r-axSpA more male w/ hi CRP. nr-axSpA had more inflam LBP, +FHx SpA. SpA Dx made without sacroiliitis in 12%; only 2/38 later developed sacroiliitis https://t.co/xPlGwZ7Kjk https://t.co/E7dNVar6dZ
Dr. John Cush @RheumNow( View Tweet )
Sun Pharma buys out Organon w/ $11.75 billion buyout. Both generated $6.2 billion in 2025 sales. Organon spun off from Merck in 2021, specializes in women’s health and is top 7 in biosimilars. Sun is into dermatology, ophthalmology and oncology-dermatology. https://t.co/zb4hucTqCJ
Dr. John Cush @RheumNow( View Tweet )
Presented at AACE Annual Meeting, FREEDOM Real-World Study looked atypical femoral Fxs & found a low AFF risk - 24 AFFs w/ denosumab (0.89/1KPY) vs 397 AFFs w/ bisphosphonates (0.82/1KPY) but no active comparators & excluded pts w/ comorbidities. https://t.co/vRwkfHSXxh https://t.co/xzgC0D5ZTu
Dr. John Cush @RheumNow( View Tweet )
Neoplasia and Autoimmune Disease
Malignancy rivals cardiovascular disease as a leading cause of death in patients with systemic autoimmune diseases. Chronic inflammation and immune dysregulation can drive oncogenesis, while antitumor immune responses can trigger autoimmune phenomena (paraneoplastic syndromes, checkpoint
Read Article
Switch or Cycle - Upadacitinib vs Adalimumab in Refractory RA
After the first tumour necrosis factor inhibitor (TNFi) failure, patients with active rheumatoid arthritis (RA) responded by switching to upadacitinib, compared to cycling to a second TNFi, adalimumab.
Obesity is more than comorbidity—it’s a driver of inflammation.
At #RheumNowLive 2026, Dr. Uzma Haque breaks down weight management strategies that actually move the needle in rheumatology care.
🎧 Listen here: https://t.co/A6fbPvV2tD
#Rheumatology #Inflammation #Obesity https://t.co/RLxV44SrUB
Dr. John Cush @RheumNow( View Tweet )
“Success is not final, failure is not fatal: it is the courage to continue that counts.”
– Winston Churchill
Dr. John Cush @RheumNow( View Tweet )
Rheumatology Salaries 2025
Medscape has published its annual Physician Compensation report with physican salaries up roughly 3% and eight specialties earning more than $500,000 per annum.
https://t.co/DNe42EsxRW https://t.co/aegcNm8Pla
Dr. John Cush @RheumNow( View Tweet )
Severe thrombocytopenia (TP) assoc w/ severe APS & increased mortality. Retro study of 432 #APS pts - 142 w/ TP (33%): 13% severe TP (<50L G/L). Severe TP assoc w/ ITP & CAP -had higher mortality https://t.co/7f8VpIcEJy
Links:
Dr. John Cush @RheumNow( View Tweet )
Weight-loss drugs may affect joints directly
A new study from Aarhus University shows that the hormone GLP-1, which is mimicked in medication for diabetes and weight loss, is present in joint fluid. In the long term, this may open up new treatments for arthritis. https://t.co/HkcPUQp05H
Dr. John Cush @RheumNow( View Tweet )
NSAIDs in Inflammatory Bowel Disease?
At least some patients with inflammatory bowel disease (IBD) can safely use common drugs for musculoskeletal aches and pains, a large study of insurance claims data suggested, contradicting a widespread concern that these products can https://t.co/JeINgTWTK0
Dr. John Cush @RheumNow( View Tweet )
GI involvement occurs in 37-65% of adult IgA (IgAV) cases, w/ Sxs of abdominal pain, hematochezia, severe complications of perforation & ischemia. Dx w/ CRP, NLR, D-dimer, imaging (CT, endoscopy). Steroids w/ Mod-to-severe Dz. MMF or IVIG for refractory cases. https://t.co/vgvZnYXIOI
Dr. John Cush @RheumNow( View Tweet )
Follow the Money (4.23.2026)
Dr. Jack Cush follows the money and all the news that fits the Rheumatology Gab for this past week.
Read Article
DESIR axSpA inception cohort study of 631 pts (no HTN), found no signif association between NSAID use & incident HTN. Over 10 YRs, 88 developed HTN (HR 1.01, 1.00–1.02) https://t.co/Gs9mPwthEj https://t.co/4sfpHmFTsu
Links:
Dr. John Cush @RheumNow( View Tweet )
Chinese study of 371 pts w/ Autoimmune hepatitis (AIH) - extrahepatic autoimmune diseases (EADs) seen in 24% -Sjogren’s & autoimmune thyroid dz (9% each). ANA+ independently assoc w/ EADs (OR 2) https://t.co/NVz8MWbJch https://t.co/tjCzaDcUFI
Dr. John Cush @RheumNow( View Tweet )
Twofold Mortality in SLE
Despite declining incidence of lupus, mortality for SLE was twice that of controls in this large incident cohort study.
Ethnicity is a strong predictor of incidence and outcomes in systemic lupus erythematosus (SLE) patients. This population study used the UK Clinical Practice
ACR Endorses New Training Model for Pediatric Subspecialties
ACR
The American College of Rheumatology (ACR) welcomes the recent announcement from the American Board of Pediatrics (ABP) outlining new training models for pediatric subspecialties. Given the collaborative work ACR has engaged in over the years, this is an important step forward in reimagining
Read Article
Rheumatology Salaries 2025
Medscape has published its annual Physician Compensation report with physican salaries up roughly 3% and eight specialties earning more than $500,000 per annum.
What is the most widely shared physician concern regarding the use of augmented intelligence? Take this week's RheumIQ quiz to find out.
https://t.co/SkXNtYJk2v https://t.co/fOKS5clUz5
Links:
Dr. John Cush @RheumNow( View Tweet )
Do patients with chronic pain have double the rates of smoking compared to those without pain? Take this week's RheumIQ quiz to find out.
https://t.co/rmB55KC7Zh https://t.co/ms3G9uBMd5
Links:
Dr. John Cush @RheumNow( View Tweet )
Aspirin Cardiovascular Prevention in Giant Cell Arteritis
A retrospective target trial emulations has shown that low-dose aspirin (ASA) given with a giant cell arteritis (GCA) diagnosis is associated with a lower risk of major adverse cardiovascular events (MACE), but a higher risk of GI bleeding.
Read Article
Weight-loss drugs may affect joints directly
EulrekAlert!
A new study from Aarhus University shows that the hormone GLP-1, which is mimicked in medication for diabetes and weight loss, is present in joint fluid. In the long term, this may open up new treatments for arthritis.
Rsearchers from the Department of Biomedicine at Aarhus
IN 2025 DTC TV ad spending by top 10 incr to $2.67 billion (up from $2.1 B). Rheum Drugs in top 3:
1. Skyrizi $440 million
2. Tremfya $431 M
3. Rinvoq $376 M
https://t.co/EsWgUqUy9Z https://t.co/zVHdVA2puZ
Dr. John Cush @RheumNow( View Tweet )
Therapeutic Updates
5-Year Results of an IL-23 Inhibitor in Patients With PsA
Sponsored by AbbVie Medical Affairs + Health Impact
Dr. Alvin Wells and Dr. Shikha Singla share their clinical perspectives on using an IL–23 inhibitor to manage patients with PsA throughout their treatment journey in the context of 5-year data from the KEEPsAKE trial program.
Read Post
Poster Hall
Recent Blogs
At first, it seemed similar to many other such sessions – a circle of folding chairs, a group of colleagues whose visages exuded understanding and acceptance – but this was special. I started the meeting…. “Hi, my name is Artie.”
Read Post
Podcasts
ACR 2025 Daily Podcasts Day4a-
ACR 2025 Daily Podcasts Day3a
ACR 2025 CAR-T Topic Podcasts Compilation 1
